by Elena Iemma | May 13, 2021 | News
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method...
by Adam | Mar 27, 2020 | News
March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen...
